Copyright Reports & Markets. All rights reserved.

Global Dual GLP-1R/GIPR Receptor Agonist Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Injection
    • 1.3.3 Oral Administration
  • 1.4 Market Analysis by Receptor Agonist Properties
    • 1.4.1 Overview: Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Receptor Agonist Properties: 2021 Versus 2025 Versus 2032
    • 1.4.2 Balanced
    • 1.4.3 Biased
  • 1.5 Market Analysis by Medicinal Efficacy
    • 1.5.1 Overview: Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Medicinal Efficacy: 2021 Versus 2025 Versus 2032
    • 1.5.2 Long-acting
    • 1.5.3 Short-acting
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Diabetes
    • 1.6.3 Obesity
    • 1.6.4 Others
  • 1.7 Global Dual GLP-1R/GIPR Receptor Agonist Market Size & Forecast
    • 1.7.1 Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (2021-2032)
    • 1.7.3 Global Dual GLP-1R/GIPR Receptor Agonist Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Eli Lilly
    • 2.1.1 Eli Lilly Details
    • 2.1.2 Eli Lilly Major Business
    • 2.1.3 Eli Lilly Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.1.4 Eli Lilly Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Eli Lilly Recent Developments/Updates
  • 2.2 Roche
    • 2.2.1 Roche Details
    • 2.2.2 Roche Major Business
    • 2.2.3 Roche Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.2.4 Roche Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Roche Recent Developments/Updates
  • 2.3 Viking Therapeutics
    • 2.3.1 Viking Therapeutics Details
    • 2.3.2 Viking Therapeutics Major Business
    • 2.3.3 Viking Therapeutics Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.3.4 Viking Therapeutics Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Viking Therapeutics Recent Developments/Updates
  • 2.4 Ascletis Pharma
    • 2.4.1 Ascletis Pharma Details
    • 2.4.2 Ascletis Pharma Major Business
    • 2.4.3 Ascletis Pharma Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.4.4 Ascletis Pharma Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Ascletis Pharma Recent Developments/Updates
  • 2.5 Jiangsu Hengrui Medicine
    • 2.5.1 Jiangsu Hengrui Medicine Details
    • 2.5.2 Jiangsu Hengrui Medicine Major Business
    • 2.5.3 Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.5.4 Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Jiangsu Hengrui Medicine Recent Developments/Updates
  • 2.6 East China Pharmaceutical
    • 2.6.1 East China Pharmaceutical Details
    • 2.6.2 East China Pharmaceutical Major Business
    • 2.6.3 East China Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.6.4 East China Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 East China Pharmaceutical Recent Developments/Updates
  • 2.7 Tonghua Dongbao Pharmaceutical
    • 2.7.1 Tonghua Dongbao Pharmaceutical Details
    • 2.7.2 Tonghua Dongbao Pharmaceutical Major Business
    • 2.7.3 Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.7.4 Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
  • 2.8 Lepu Medical Technology
    • 2.8.1 Lepu Medical Technology Details
    • 2.8.2 Lepu Medical Technology Major Business
    • 2.8.3 Lepu Medical Technology Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.8.4 Lepu Medical Technology Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Lepu Medical Technology Recent Developments/Updates
  • 2.9 Hansoh Pharma
    • 2.9.1 Hansoh Pharma Details
    • 2.9.2 Hansoh Pharma Major Business
    • 2.9.3 Hansoh Pharma Dual GLP-1R/GIPR Receptor Agonist Product and Services
    • 2.9.4 Hansoh Pharma Dual GLP-1R/GIPR Receptor Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Hansoh Pharma Recent Developments/Updates

3 Competitive Environment: Dual GLP-1R/GIPR Receptor Agonist by Manufacturer

  • 3.1 Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Manufacturer (2021-2026)
  • 3.3 Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Dual GLP-1R/GIPR Receptor Agonist by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Dual GLP-1R/GIPR Receptor Agonist Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Dual GLP-1R/GIPR Receptor Agonist Manufacturer Market Share in 2025
  • 3.5 Dual GLP-1R/GIPR Receptor Agonist Market: Overall Company Footprint Analysis
    • 3.5.1 Dual GLP-1R/GIPR Receptor Agonist Market: Region Footprint
    • 3.5.2 Dual GLP-1R/GIPR Receptor Agonist Market: Company Product Type Footprint
    • 3.5.3 Dual GLP-1R/GIPR Receptor Agonist Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Dual GLP-1R/GIPR Receptor Agonist Market Size by Region
    • 4.1.1 Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Region (2021-2032)
    • 4.1.3 Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Region (2021-2032)
  • 4.2 North America Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032)
  • 4.3 Europe Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032)
  • 4.5 South America Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2032)
  • 5.2 Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Type (2021-2032)
  • 5.3 Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2032)
  • 6.2 Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Application (2021-2032)
  • 6.3 Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2032)
  • 7.2 North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2032)
  • 7.3 North America Dual GLP-1R/GIPR Receptor Agonist Market Size by Country
    • 7.3.1 North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2032)
  • 8.2 Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2032)
  • 8.3 Europe Dual GLP-1R/GIPR Receptor Agonist Market Size by Country
    • 8.3.1 Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Market Size by Region
    • 9.3.1 Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2032)
  • 10.2 South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2032)
  • 10.3 South America Dual GLP-1R/GIPR Receptor Agonist Market Size by Country
    • 10.3.1 South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Market Size by Country
    • 11.3.1 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Dual GLP-1R/GIPR Receptor Agonist Market Drivers
  • 12.2 Dual GLP-1R/GIPR Receptor Agonist Market Restraints
  • 12.3 Dual GLP-1R/GIPR Receptor Agonist Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Dual GLP-1R/GIPR Receptor Agonist and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Dual GLP-1R/GIPR Receptor Agonist
  • 13.3 Dual GLP-1R/GIPR Receptor Agonist Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Dual GLP-1R/GIPR Receptor Agonist Typical Distributors
  • 14.3 Dual GLP-1R/GIPR Receptor Agonist Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Dual GLP-1R/GIPR Receptor Agonist market size was valued at US$ 31519 million in 2025 and is forecast to a readjusted size of US$ 65873 million by 2032 with a CAGR of 11.0% during review period.
    In 2025, global Dual GLP-1R/GIPR Receptor Agonist production reached approximately 161.44 M Units, with an average global market price of around 189.74 USD per Unit.
    A Dual GLP-1R/GIPR Receptor Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available Dual GLP-1R/GIPR Receptor Agonist product in the world.
    Dual GLP-1R/GIPR Receptor Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.
    The upstream raw materials for Dual GLP-1R/GIPR Receptor Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.
    The single-line production capacity of Dual GLP-1R/GIPR Receptor Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
    This report is a detailed and comprehensive analysis for global Dual GLP-1R/GIPR Receptor Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Dual GLP-1R/GIPR Receptor Agonist market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Dual GLP-1R/GIPR Receptor Agonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Dual GLP-1R/GIPR Receptor Agonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Dual GLP-1R/GIPR Receptor Agonist market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Dual GLP-1R/GIPR Receptor Agonist
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Dual GLP-1R/GIPR Receptor Agonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Dual GLP-1R/GIPR Receptor Agonist market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Injection
    Oral Administration
    Market segment by Receptor Agonist Properties
    Balanced
    Biased
    Market segment by Medicinal Efficacy
    Long-acting
    Short-acting
    Market segment by Application
    Diabetes
    Obesity
    Others
    Major players covered
    Eli Lilly
    Roche
    Viking Therapeutics
    Ascletis Pharma
    Jiangsu Hengrui Medicine
    East China Pharmaceutical
    Tonghua Dongbao Pharmaceutical
    Lepu Medical Technology
    Hansoh Pharma
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Dual GLP-1R/GIPR Receptor Agonist product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Dual GLP-1R/GIPR Receptor Agonist, with price, sales quantity, revenue, and global market share of Dual GLP-1R/GIPR Receptor Agonist from 2021 to 2026.
    Chapter 3, the Dual GLP-1R/GIPR Receptor Agonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Dual GLP-1R/GIPR Receptor Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Dual GLP-1R/GIPR Receptor Agonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Dual GLP-1R/GIPR Receptor Agonist.
    Chapter 14 and 15, to describe Dual GLP-1R/GIPR Receptor Agonist sales channel, distributors, customers, research findings and conclusion.

    Buy now